Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BY-NC-ND 4.0Mediastinum

AB040. Outcomes and prognostic factors in thymic epithelial tumors: a Brazilian retrospective cohort

4 affiliations
  1. 1Department of Medical Oncology, D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil
  2. 2Oncologia D’Or, Salvador, Bahia, Brazil
  3. 3Department of Medical Oncology, Cancer Institute of the State of São Paulo, São Paulo, Brazil
  4. 4Oncologia D’Or, Recife, Pernambuco, Brazil

Abstract

Background: Thymic epithelial tumors (TETs) are rare malignant mediastinal neoplasms with heterogeneous clinical behavior, ranging from indolent thymomas to aggressive thymic carcinomas. Although thymic carcinoma is generally associated with poorer outcomes, the independent contribution of histological subtype after adjusting for disease stage remains uncertain. We evaluated survival outcomes and prognostic factors in a retrospective cohort of patients with TETs.

Methods: We retrospectively analyzed 71 patients with histologically confirmed TETs (56 thymomas and 15 thymic carcinomas). Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Univariate Cox regression identified factors associated with DFS. Multivariate Cox models, including histological subtype and disease stage, were constructed using either the Masaoka-Koga or the tumor-node-metastasis (TNM) 9th edition (AJCC/UICC) staging systems. Proportional hazards assumptions were assessed using Schoenfeld residuals.

Results: The median age was 55 years [interquartile range (IQR): 46–64]; 55% were male, 87% underwent surgery, and 45% received radiotherapy. During follow-up, 14 patients (19.7%) experienced recurrence/progression, and six patients (8.5%) died. Death occurred in 4 of 15 patients with thymic carcinoma (27%) versus 2 of 56 with thymoma (3.6%; P=0.008), and recurrence/progression in 6 of 15 (40%) versus 8 of 56 (14%; P=0.02). In the univariate analysis, thymic carcinoma (HR 3.53; 95% CI: 1.18–10.57) and advanced disease stage (Masaoka-Koga III/IV: HR 6.80; 95% CI: 1.84–25.13; TNM III/IV: HR 6.63; 95% CI: 1.81–24.32) were associated with inferior DFS. However, after adjustment for stage, the histological subtype was no longer independently associated with DFS. Advanced stage remained the only independent predictor of recurrence (Masaoka-Koga III/IV: HR 5.80; 95% CI: 1.25–26.78; P=0.02; TNM III/IV: HR 5.53; 95% CI: 1.28–23.92; P=0.02). No violations of the proportional hazards assumption were observed.

Conclusions: Although thymic carcinoma was associated with worse unadjusted survival, disease stage, rather than histological subtype, was the primary independent predictor of disease-free survival in this cohort. The consistency of the findings, using both the Masaoka-Koga and TNM staging systems, reinforces the central prognostic role of disease stage and supports its use for risk stratification in patients with thymic epithelial tumors.

Related

  1. Clinical characteristics, long-term outcomes, and prognostic factors in linear IgA bullous dermatosis: A retrospective cohort study across the age spectrum in China, 2008-2025.
    Zhe Wang, Zhenzhen Wang, Wenchao Li +9
    JAAD internationalPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Clinical outcomes and prognostic factors of Ommaya reservoir-based intrathecal chemotherapy in lung cancer leptomeningeal metastasis: a retrospective cohort study
    Yuechao Yang, Mingtao Feng, Yu Xuan Ong +12
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Treatment Outcomes and Prognostic Factors in Children with Myeloid Leukemia Associated with Down Syndrome: A Nationwide Polish Retrospective Study
    Katarzyna Pawińska-Wąsikowska, Małgorzata Czogała, Karolina Bukowska-Strakova +28
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Evaluation of clinical outcomes and prognostic factors in patients with metastatic appendiceal adenocarcinoma treated with first-line chemotherapy: A multi-institutional retrospective study
    Koshiro Fukuda, Hiroki Osumi, Atsuo Takashima +15
    Therapeutic Advances in Medical OncologyPeer-reviewedCC BYFull textSurgery & anaesthesiaDOAJ
  5. Radiographic outcomes and prognostic factors after protocol-defined prolonged abduction containment for Legg-Calvé-Perthes disease: a 427-hip retrospective cohort study.
    Tiantian Xia, Fengjie Zhang, Jiaru Liao +4
    BMC musculoskeletal disordersPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
BibTeX
@article{souza2026ab040,
  title = {{AB040. Outcomes and prognostic factors in thymic epithelial tumors: a Brazilian retrospective cohort}},
  author = {Alice S. de Souza and Viviane S. F. Silva and Viviane P. B. de Souza and Leonardo V. L. Ferreira and Mauro Zukin and Eldsamira Mascarenhas and Milena P. Mak and Carla R. de Azevedo and Clarissa Baldotto},
  journal = {Mediastinum},
  year = {2026},
  month = oct,
  doi = {10.21037/med-26-ab040},
  url = {https://doi.org/10.21037/med-26-ab040},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - AB040. Outcomes and prognostic factors in thymic epithelial tumors: a Brazilian retrospective cohort
AU  - Alice S. de Souza
AU  - Viviane S. F. Silva
AU  - Viviane P. B. de Souza
AU  - Leonardo V. L. Ferreira
AU  - Mauro Zukin
AU  - Eldsamira Mascarenhas
AU  - Milena P. Mak
AU  - Carla R. de Azevedo
AU  - Clarissa Baldotto
PY  - 2026
DA  - 2026/10/30
JO  - Mediastinum
DO  - 10.21037/med-26-ab040
UR  - https://doi.org/10.21037/med-26-ab040
AB  - Background: Thymic epithelial tumors (TETs) are rare malignant mediastinal neoplasms with heterogeneous clinical behavior, ranging from indolent thymomas to aggressive thymic carcinomas. Although thymic carcinoma is generally associated with poorer outcomes, the independent contribution of histological subtype after adjusting for disease stage remains uncertain. We evaluated survival outcomes and prognostic factors in a retrospective cohort of patients with TETs.  Methods: We retrospectively analyzed 71 patients with histologically confirmed TETs (56 thymomas and 15 thymic carcinomas). Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Univariate Cox regression identified factors associated with DFS. Multivariate Cox models, including histological subtype and disease stage, were constructed using either the Masaoka-Koga or the tumor-node-metastasis (TNM) 9th edition (AJCC/UICC) staging systems. Proportional hazards assumptions were assessed using Schoenfeld residuals.  Results: The median age was 55 years [interquartile range (IQR): 46–64]; 55% were male, 87% underwent surgery, and 45% received radiotherapy. During follow-up, 14 patients (19.7%) experienced recurrence/progression, and six patients (8.5%) died. Death occurred in 4 of 15 patients with thymic carcinoma (27%) versus 2 of 56 with thymoma (3.6%; P=0.008), and recurrence/progression in 6 of 15 (40%) versus 8 of 56 (14%; P=0.02). In the univariate analysis, thymic carcinoma (HR 3.53; 95% CI: 1.18–10.57) and advanced disease stage (Masaoka-Koga III/IV: HR 6.80; 95% CI: 1.84–25.13; TNM III/IV: HR 6.63; 95% CI: 1.81–24.32) were associated with inferior DFS. However, after adjustment for stage, the histological subtype was no longer independently associated with DFS. Advanced stage remained the only independent predictor of recurrence (Masaoka-Koga III/IV: HR 5.80; 95% CI: 1.25–26.78; P=0.02; TNM III/IV: HR 5.53; 95% CI: 1.28–23.92; P=0.02). No violations of the proportional hazards assumption were observed.  Conclusions: Although thymic carcinoma was associated with worse unadjusted survival, disease stage, rather than histological subtype, was the primary independent predictor of disease-free survival in this cohort. The consistency of the findings, using both the Masaoka-Koga and TNM staging systems, reinforces the central prognostic role of disease stage and supports its use for risk stratification in patients with thymic epithelial tumors.
SN  - 2522-6711
ER  -